| CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency N Matharu, S Rattanasopha, S Tamura, L Maliskova, Y Wang, A Bernard, ... Science 363 (6424), eaau0629, 2019 | 268 | 2019 |
| Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors N Vidula, TA Rich, O Sartor, J Yen, A Hardin, T Nance, MB Lilly, ... Clinical Cancer Research 26 (11), 2546-2555, 2020 | 40 | 2020 |
| Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers Y Kobayashi, C Chhoeu, J Li, KS Price, LA Kiedrowski, JL Hutchins, ... Nature 603 (7900), 335-342, 2022 | 28 | 2022 |
| Comparative Genomic Characterization of the Multimammate Mouse Mastomys coucha A Hardin, KA Nevonen, WL Eckalbar, L Carbone, N Ahituv Molecular biology and evolution 36 (12), 2805-2812, 2019 | 11 | 2019 |
| Clinical utility of microsatellite instability (MSI-H) identified on liquid biopsy in advanced gastrointestinal cancers (aGI). PM Kasi, SJ Klempner, JS Starr, A Shergill, LA Bucheit, C Weipert, J Liao, ... Journal of Clinical Oncology 40 (4_suppl), 56-56, 2022 | 6 | 2022 |
| Spectrum of FGFR2/3 alterations in cell-free DNA of patients with advanced urothelial carcinoma P Grivas, LA Kiedrowski, GP Sonpavde, SV Gupta, RA Thomas, ... Bladder Cancer 7 (2), 143-148, 2021 | 3 | 2021 |
| A molecular characterization of spontaneous frameshift mutagenesis within the trpA gene of Escherichia coli A Hardin, CF Villalta, M Doan, M Jabri, V Chockalingham, SJ White, ... DNA repair 6 (2), 177-189, 2007 | 3 | 2007 |
| The liquid biopsy Guardant360 CDx has robust performance at low inputs allowing for high rate of returning patient results AO Richardson, A Hardin, S Shukla, J Zhao, C Barbacioru, H Beas, ... Cancer Research 81 (13_Supplement), 572-572, 2021 | 2 | 2021 |
| Abstract PS18-15: Real-world clinical-genomic data identifies the ESR1 clonal and subclonal circulating tumor DNA (ctDNA) landscape and provides insight into clinical outcomes D Hanna, J Hutchins, J Yu, E Marino, N Kumar, R Kucharlapati, R Chavali, ... Cancer Research 81 (4_Supplement), PS18-15-PS18-15, 2021 | 2 | 2021 |
| Abstract PS18-28: Genomic heterogeneity and associated clinical outcomes of breast cancers treated with CDK4/6 inhibitors: Insights from real-world clinical genomic data J Yu, C Ton, E Marino, N Kumar, R Kucharlapati, R Chavali, G Nayak, ... Cancer Research 81 (4_Supplement), PS18-28-PS18-28, 2021 | 1 | 2021 |
| PIK3CA mutational analysis using cell-free DNA next-generation sequencing detects activating mutations that may be missed with targeted hot-spot testing LA Kiedrowski, D Juric, AI Hardin, KS Price, RJ Nagy, CL Arteaga, ... CANCER RESEARCH 80 (4), 2020 | 1 | 2020 |
| Determining a dynamic quality metric of a biopsy sample S FAIRCLOUGH, AI HARDIN, D Hanna, CY Lee US Patent App. 18/451,739, 2024 | | 2024 |
| Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes PM Kasi, LA Bucheit, J Liao, J Starr, P Barata, SJ Klempner, D Gandara, ... JCO Precision Oncology 7, e2300118, 2023 | | 2023 |
| Analytical and clinical validation of a ctDNA assay for detecting copy number loss and structural rearrangement variants contributing to homologous recombination and repair … J Yen, L Drusbosky, C Weipert, N Zhang, D Hanna, C Barbacioru, ... CANCER RESEARCH 82 (4), 2022 | | 2022 |
| Abstract P5-13-29: Analytical and clinical validation of a ctDNA assay for detecting copy number loss and structural rearrangement variants contributing to homologous … J Yen, L Drusbosky, C Weipert, N Zhang, D Hanna, C Barbacioru, ... Cancer Research 82 (4_Supplement), P5-13-29-P5-13-29, 2022 | | 2022 |
| Significance modeling of clonal-level absence of target variants A Artsiomenka, AI Hardin, S Fairclough, M Sikora, C Barbacioru US Patent App. 17/162,897, 2021 | | 2021 |
| Genomic heterogeneity and associated clinical outcomes of breast cancers treated with CDK4/6 inhibitors: Insights from real-world clinical genomic data J Yu, C Ton, E Marino, N Kumar, R Kucharlapati, R Chavali, G Nayak, ... CANCER RESEARCH 81 (4), 2021 | | 2021 |
| Development of a clinical-genomic database to study tumor evolution and molecular biomarkers of drug resistance in a real-world setting N Kumar, R Kucharlapati, A Hardin, VM Raymond, S Fairclough, K Lang Cancer Research 80 (16_Supplement), 4421-4421, 2020 | | 2020 |
| Abstract P4-10-15: PIK3CA mutational analysis using cell-free DNA next-generation sequencing detects activating mutations that may be missed with targeted hot … LA Kiedrowski, D Juric, AI Hardin, KS Price, RJ Nagy, CL Arteaga, ... Cancer Research 80 (4_Supplement), P4-10-15-P4-10-15, 2020 | | 2020 |
| Detection of allele specific loss of heterozygosity in 70,000 patients with ctDNA J Zhao, SR Fairclough, D Chudova, R Lanman, AA Talasaz, A Hardin Cancer Research 79 (13_Supplement), 3769-3769, 2019 | | 2019 |
Christopher VillaltaUniversity of California, BerkeleyVerified email at berkeley.edu
